Tarsus Pharmaceuticals (TARS) Accounts Payables (2019 - 2026)

Tarsus Pharmaceuticals' Accounts Payables history runs 8 years deep, the most recent figure standing at $24.1 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 68.4% year-over-year to $24.1 million; the TTM figure through Mar 2026 stood at $24.1 million (down 68.4% YoY), while the FY2025 annual figure was $101.5 million, up 977.92% from the prior year.
• Accounts Payables was $24.1 million for Q1 2026 at Tarsus Pharmaceuticals, down from $101.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $103.5 million in Q3 2025 to a low of $8.9 million in Q2 2022.
• Historically, Accounts Payables has averaged $36.8 million across 5 years, with a median of $23.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables soared 977.92% in 2025, then sank 68.4% in 2026.
• A 5-year view of Accounts Payables shows it stood at $9.9 million in 2022, then soared by 139.06% to $23.7 million in 2023, then slumped by 60.24% to $9.4 million in 2024, then jumped by 977.92% to $101.5 million in 2025, then slumped by 76.23% to $24.1 million in 2026.
• The last three Accounts Payables figures came in at $24.1 million (Q1 2026), $101.5 million (Q4 2025), and $103.5 million (Q3 2025), per Business Quant data.